Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis
ZORYVE foam offers quick disease clearance and major reduction in itch, with nearly 80% of individuals meeting the primary efficacy endpoint of IGA Success and just more than